紫杉醇联合卡铂化疗同步放疗治疗中晚期宫颈癌近期疗效观察

发布时间：2018-06-23 22:08

本文选题：宫颈癌 + 中晚期　；参考：《山东医药》2017年06期

【摘要】：目的观察紫杉醇联合卡铂化疗同步放疗治疗中晚期宫颈癌患者的临床疗效。方法将52例中晚期宫颈癌患者随机分为两组各26例,观察组给予紫杉醇联合卡铂化疗同步放疗,对照组给予单纯放疗。治疗前后检测两组血清鳞状细胞癌相关抗原(SCCAg)、细胞角蛋白19片段(CYFRA21-1)水平,治疗后3~6个月按照WHO实体瘤疗效标准评价近期疗效,记录治疗期间的不良反应。结果两组治疗后血清SCCAg、CYFRA21-1水平均低于治疗前(P均0.05),观察组治疗后SCCAg、CYFRA21-1水平低于对照组(P均0.05);观察组治疗总有效率为80.77%,高于对照组的46.15%(P0.05);观察组不良反应率为34.62%,低于对照组的76.92%(P0.05)。结论中晚期宫颈癌患者采用紫杉醇联合卡铂化疗同步放疗的近期疗效较单纯放疗更为显著,且不良反应少。
[Abstract]:Objective to observe the clinical effect of paclitaxel combined with carboplatin chemotherapy in the treatment of advanced cervical cancer. Methods 52 patients with advanced cervical cancer were randomly divided into two groups: the observation group received paclitaxel combined with carboplatin chemotherapy and the control group received radiotherapy alone. The serum levels of SCCAg and CYFRA21-1 were measured before and after treatment. The short-term efficacy of SCCAg and CYFRA21-1 were evaluated 3 ~ 6 months after treatment and adverse reactions were recorded according to WHO criteria. Results after treatment, the levels of serum SCCAgfRA21-1 in both groups were lower than those before treatment (P 0.05), and the levels of SCCAgCYFRA21-1 in the observation group were lower than those in the control group (P 0.05), the total effective rate of the observation group was 80.77, which was higher than 46.15% of the control group (P0.05), the adverse reaction rate of the observation group was 34.62%, lower than that of the control group (76.92%) (P0.05). Conclusion the short-term efficacy of paclitaxel combined with carboplatin chemotherapy in patients with advanced cervical cancer is more significant than that of radiotherapy alone, and the adverse reactions are less.
【作者单位】：承德市中心医院;
【分类号】：R737.33

【参考文献】